|
1）本多 彰，池上 正，屋良昭一郎，他．酸化ステロールと生活習慣病．日本予防医学会雑誌．2014; 9: 117-22
|
|
|
|
|
2）Babiker A, Andersson O, Lund E, et al. Elimination of cholesterol in macrophages and endothelial cells by the sterol 27-hydroxylase mechanism. J Biol Chem. 1997; 272: 26253-61
|
|
|
|
|
3）Bjorkhem I, Lutjohann D, Diczfalusy U, et al. Cholesterol homeostasis in human brain: turnover of 24S-hydroxycholesterol and evidence for a cerebral origin of most of this oxysterol in the circulation. J Lipid Res. 1998; 39: 1594-600
|
|
|
|
|
|
4）Spann NJ, Glass CK. Sterols and oxysterols in immune cell function. Nat Immunol. 2013; 14: 893-900
|
|
|
|
|
|
5）Radhakrishnan A, Ikeda Y, Kwon HJ, et al. Sterol-regulated transport of SREBPs from endoplasmic reticulum to Golgi: oxysterols block transport by binding to Insig. Proc Natl Acad Sci U S A. 2007; 104: 6511-8
|
|
|
|
|
|
6）Liu C, Yang XV, Wu J, et al. Oxysterols direct B-cell migration through EBI2. Nature. 2011; 475: 519-23
|
|
|
|
|
|
7）Hannedouche S, Zhang J, Yi T, et al. Oxysterols direct immune cell migration via EBI2. Nature. 2011; 475: 524-7
|
|
|
|
|
|
8）Umetani M, Domoto H, Gormley AK, et al. 27-Hydroxycholesterol is an endogenous SERM that inhibits the cardiovascular effects of estrogen. Nat Med. 2007; 13: 1185-92
|
|
|
|
|
|
9）Ducheix S, Montagner A, Theodorou V, et al. The liver X receptor: a master regulator of the gut-liver axis and a target for non alcoholic fatty liver disease. Biochem Pharmacol. 2013; 86: 96-105
|
|
|
|
|
|
10）Ikegami T, Hyogo H, Honda A, et al. Increased serum liver X receptor ligand oxysterols in patients with non-alcoholic fatty liver disease. J Gastroenterol. 2012; 47: 1257-66
|
|
|
|
|
|
11）Nakamuta M, Fujino T, Yada R, et al. Impact of cholesterol metabolism and the LXRα-SREBP-1c pathway on nonalcoholic fatty liver disease. Int J Mol Med. 2009; 23: 603-8
|
|
|
|
|
|
12）Ahn SB, Jang K, Jun DW, et al. Expression of liver X receptor correlates with intrahepatic inflammation and fibrosis in patients with nonalcoholic fatty liver disease. Dig Dis Sci. 2014; 59: 2975-82
|
|
|
|
|
|
13）Van Rooyen DM, Larter CZ, Haigh WG, et al. Hepatic free cholesterol accumulates in obese, diabetic mice and causes nonalcoholic steatohepatitis. Gastroenterology. 2011; 141: 1393-403
|
|
|
|
|
|
14）Musso G, Gambino R, Cassader M. Cholesterol metabolism and the pathogenesis of non-alcoholic steatohepatitis. Prog Lipid Res. 2013; 52: 175-91
|
|
|
|
|
|
15）Ichimura M, Kawase M, Masuzumi M, et al. High-fat and high-cholesterol diet rapidly induces non-alcoholic steatohepatitis with advanced fibrosis in Sprague-Dawley rats. Hepatol Res. 2015; 45: 458-69
|
|
|
|
|
|
16）Bieghs V, Verheyen F, van Gorp PJ, et al. Internalization of modified lipids by CD36 and SR-A leads to hepatic inflammation and lysosomal cholesterol storage in Kupffer cells. PLoS One. 2012; 7: e34378
|
|
|
|
|
|
17）Tomita K, Teratani T, Suzuki T, et al. Free cholesterol accumulation in hepatic stellate cells: mechanism of liver fibrosis aggravation in non-alcoholic steatohepatitis in mice. Hepatology. 2014; 59: 154-69
|
|
|
|
|
|
18）Ferre N, Martinez-Clemente M, Lopez-Parra M, et al. Increased susceptibility to exacerbated liver injury in hypercholesterolemic ApoE-deficient mice: potential involvement of oxysterols. Am J Physiol Gastrointest Liver Physiol. 2009; 296: G553-62
|
|
|
|
|
|
19）Wouters K, van Bilsen M, van Gorp PJ, et al. Intrahepatic cholesterol influences progression, inhibition and reversal of non-alcoholic steatohepatitis in hyperlipidemic mice. FEBS Lett. 2010; 584: 1001-5
|
|
|
|
|
|
20）Beaven SW, Wroblewski K, Wang J, et al. Liver X receptor signaling is a determinant of stellate cell activation and susceptibility to fibrotic liver disease. Gastroenterology. 2011; 140: 1052-62
|
|
|
|
|
|
21）Liu Y, Han X, Bian Z, et al. Activation of liver X receptors attenuates endotoxin-induced liver injury in mice with nonalcoholic fatty liver disease. Dig Dis Sci. 2012; 57: 390-8
|
|
|
|
|
|
22）Bieghs V, Hendrikx T, van Gorp PJ, et al. The cholesterol derivative 27-hydroxycholesterol reduces steatohepatitis in mice. Gastroenterology. 2013; 144: 167-78
|
|
|
|
|
|
23）Hendrikx T, Jeurissen ML, Bieghs V, et al. Hematopoietic overexpression of Cyp27a1 reduces hepatic inflammation independently of 27-hydroxycholesterol levels in Ldlr(-/-) mice. J Hepatol. 2015; 62: 430-6
|
|
|
|
|
|
24）Berrodin TJ, Shen Q, Quinet EM, et al. Identification of 5α,6α-epoxycholesterol as a novel modulator of liver X receptor activity. Mol Pharmacol. 2010; 78: 1046-58
|
|
|
|
|
|
25）Xu L, Kim JK, Bai Q, et al. 5-cholesten-3β,25-diol 3-sulfate decreases lipid accumulation in diet-induced nonalcoholic fatty liver disease mouse model. Mol Pharmacol. 2013; 83: 648-58
|
|
|
|
|
|
26）Wooten JS, Wu H, Raya J, et al. The influence of an obesogenic diet on oxysterol metabolism in C57BL/6J mice. Cholesterol. 2014; 2014: 843468
|
|
|
|
|
|
27）Kratzer A, Buchebner M, Pfeifer T, et al. Synthetic LXR agonist attenuates plaque formation in apoE-/- mice without inducing liver steatosis and hypertriglyceridemia. J Lipid Res. 2009; 50: 312-26
|
|
|
|
|
|
28）Hoang MH, Jia Y, Jun HJ, et al. Fucosterol is a selective liver X receptor modulator that regulates the expression of key genes in cholesterol homeostasis in macrophages, hepatocytes, and intestinal cells. J Agric Food Chem. 2012; 60: 11567-75
|
|
|
|
|
|
29）Honda A, Matsuzaki Y. Cholesterol and chronic hepatitis C virus infection. Hepatol Res. 2011; 41: 697-710
|
|
|
|
|
|
30）Fujino T, Nakamuta M, Yada R, et al. Expression profile of lipid metabolism-associated genes in hepatitis C virus-infected human liver. Hepatol Res. 2010; 40: 923-9
|
|
|
|
|
|
31）Liu SY, Aliyari R, Chikere K, et al. Interferon-inducible cholesterol-25-hydroxylase broadly inhibits viral entry by production of 25-hydroxycholesterol. Immunity. 2013; 38: 92-105
|
|
|
|
|
|
32）Blanc M, Hsieh WY, Robertson KA, et al. The transcription factor STAT-1 couples macrophage synthesis of 25-hydroxycholesterol to the interferon antiviral response. Immunity. 2013; 38: 106-18
|
|
|
|
|
|
33）Xiang Y, Tang JJ, Tao W, et al. Identification of cholesterol 25-hydroxylase as a novel host restriction factor and a part of the primary innate immune responses against hepatitis C virus infection. J Virol. 2015; 89: 6805-16
|
|
|
|
|
|
34）Anggakusuma, Romero-Brey I, Berger C, et al. Interferon-inducible cholesterol-25-hydroxylase restricts hepatitis C virus replication through blockage of membranous web formation. Hepatology. 2015; 62: 702-14
|
|
|
|
|
|
35）Chen Y, Wang S, Yi Z, et al. Interferon-inducible cholesterol-25-hydroxylase inhibits hepatitis C virus replication via distinct mechanisms. Sci Rep. 2014; 4: 7242
|
|
|
|
|
|
36）Ikegami T, Honda A, Miyazaki T, et al. Increased serum oxysterol concentrations in patients with chronic hepatitis C virus infection. Biochem Biophys Res Commun. 2014; 446: 736-40
|
|
|
|
|
|
37）De Boussac H, Alioui A, Viennois E, et al. Oxysterol receptors and their therapeutic applications in cancer conditions. Expert Opin Ther Targets. 2013; 17: 1029-38
|
|
|
|
|
|
38）Traversari C, Sozzani S, Steffensen KR, et al. LXR-dependent and -independent effects of oxysterols on immunity and tumor growth. Eur J Immunol. 2014; 44: 1896-903
|
|
|
|
|
|
39）Bovenga F, Sabba C, Moschetta A. Uncoupling nuclear receptor LXR and cholesterol metabolism in cancer. Cell Metab. 2015; 21: 517-26
|
|
|
|
|
|
40）Lu M, Hu XH, Li Q, et al. A specific cholesterol metabolic pathway is established in a subset of HCCs for tumor growth. J Mol Cell Biol. 2013; 5: 404-15
|
|
|
|
|